Ubs Group Ag Nanobiotix S.A. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Nanobiotix S.A. stock. As of the latest transaction made, Ubs Group Ag holds 3,100 shares of NBTX stock, worth $12,617. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,100

Previous 3,100 -0.0%

Holding current value

$12,617

Previous $15,000 13.33%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$5.34 - $9.19 $3,770 - $6,488	-706 Reduced 18.55%	3,100 $22,000
Q3 2023 Nov 09, 2023	SELL	$5.03 - $10.76 $985 - $2,108	-196 Reduced 4.9%	3,806 $33,000
Q2 2023 Aug 11, 2023	BUY	$1.98 - $6.68 $1,983 - $6,693	1,002 Added 33.4%	4,002 $20,000
Q1 2023 May 12, 2023	SELL	$0.0 - $4.49 $0 - $3,583	-798 Reduced 21.01%	3,000 $10,000
Q4 2022 Feb 08, 2023	BUY	$3.51 - $4.18 $2,650 - $3,155	755 Added 24.81%	3,798 $13,000
Q3 2022 Nov 10, 2022	BUY	$2.32 - $4.73 $4 - $9	2 Added 0.07%	3,043 $11,000
Q2 2022 Aug 10, 2022	SELL	$3.53 - $7.44 $2,746 - $5,788	-778 Reduced 20.37%	3,041 $11,000
Q1 2022 May 16, 2022	SELL	$6.11 - $9.85 $13,405 - $21,610	-2,194 Reduced 36.49%	3,819 $26,000
Q4 2021 Feb 14, 2022	SELL	$7.13 - $13.04 $387,444 - $708,593	-54,340 Reduced 90.04%	6,013 $48,000
Q3 2021 Nov 15, 2021	BUY	$11.36 - $15.0 $6,384 - $8,430	562 Added 0.94%	60,353 $686,000
Q2 2021 Aug 13, 2021	SELL	$13.78 - $17.79 $143,187 - $184,855	-10,391 Reduced 14.81%	59,791 $824,000
Q1 2021 May 12, 2021	BUY	$14.95 - $19.68 $1.04 Million - $1.37 Million	69,836 Added 20183.82%	70,182 $1.06 Million
Q4 2020 Feb 11, 2021	BUY	$15.95 - $19.4 $5,518 - $6,712	346 New	346 $6,000

Others Institutions Holding NBTX

# of Institutions

Shares Held

6.43M

Call Options Held

Put Options Held

View Full List

About Nanobiotix S.A.

Ticker NBTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,875,900
Market Cap $142M
Description
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cance...

More about NBTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account